Fibromyalgia Syndrome (FMS): Neural Therapy as a Key to Pain Reduction and Quality of Life

Fibromyalgia syndrome (FMS) is a complex chronic pain disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive impairments. Its global prevalence is estimated at 2–3%, with women between the ages of 30 and 60 being most commonly affected. The pathophysiology of FMS is multifactorial, involving central sensitization processes, dysfunctions of pain inhibition mechanisms, and chronic inflammatory and neuroendocrine disturbances. Pathophysiological Mechanisms: • Central sensitization: Increased pain processing in the central nervous system. • Neuroendocrine dysfunction: Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, altered cortisol and serotonin levels. • Lymphatic dysfunction: Edema, inflammation, and accumulation of toxins. • Silent inflammation: Chronic inflammatory processes with elevated cytokine activity (e.g., TNF-α, IL-6). Neural Therapy as a Treatment Approach Neural therapy addresses autonomic dysregulation and restores the balance between the sympathetic and parasympathetic nervous systems. Key therapeutic strategies include: • Local infiltrations: Procaine or lidocaine injections to reduce pain sensitivity. • Segmental therapy: Treatment of spinal reflex zones to regulate the autonomic nervous system. • Interference field therapy: Identification and treatment of chronic irritative foci. Adjunctive measures, such as manual lymphatic drainage, anti-inflammatory nutrition, and micronutrient therapy, can enhance treatment efficacy. The combination of neural therapy and regulatory medicine shows promising results in reducing pain, improving sleep quality, and restoring quality of life.